Global Anti-fungal Drugs Market Growth and Trends to 2023 - Analysis by Drug Type, Therapeutic Indication, and Geography - ResearchAndMarkets.com

DUBLIN--()--The "Global Anti-fungal Drugs Market - Segmented by Drug Type, Therapeutic Indication, and Geography - Growth, Trends and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The global anti-fungal drugs market is expected to register a CAGR of 3.6% during the forecast period, 2018 to 2023.

With rising popularity of Over-The-Counter (OTC) drugs, many patients are preferring OTC drugs because these over the counter drugs are obtaining without a prescription from a healthcare professional. Numerous common and harmless fungal infections are left untreated by patients, owing to medical costs and logistical constraints. These have directly contributed to the rise in the usage of OTC drugs, owing to their ease of availability.

According to the Consumer Healthcare Products Association, more than 81% of adults use OTC medicines as their first response to minor ailments. The increased usage of OTC drugs has further contributed to the rise in anti-fungal drug sales over the years. And the other factors such as increasing awareness among the people regarding the fungal infection, and increasing number of the immune-compromised aged population are driving the market growth.

North America dominates the market due to increasing awareness of fungal infections with the growing incidence of antifungal infections and increasing government and corporate funding in the industry. While Asia-Pacific was estimated to register the fastest CAGR through the forecast period, 2018-2023.

Key Developments in the Market

  • October 2017: Gilead Sciences has Acquired the Kite Pharma, Inc.

Key Topics Covered

1. Introduction

1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

5.1 Current Market Scenario

5.2 Market Overview

5.3 Porter's Five Forces Analysis

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

6.1 Market Drivers

6.2 Market Restraints

6.3 Opportunities

6.4 Challenges

7. Market Segmentation

7.1 By Drug Type

7.2 By Therapeutic Indication

7.3 By Geography

8. Competitive Landscape

8.1 Mergers & Acquisitions

8.2 Agreements, Collaborations & Partnerships

8.3 New Product Launches

9. Key Players

9.1 Abbott Laboratories

9.2 Pfizer

9.3 GlaxoSmithKline

9.4 Bayer Healthcare

9.5 Novartis

9.6 Sanofi-Aventis

9.7 Merck & Co.

9.8 Kramer Laboratories

9.9 Enzon Pharmaceuticals

9.10 Gilead

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/s6c37h/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs